“…FAAH is widely localized throughout the brain, and FAAH-positive neurons have been found in the proximity of nerve terminals containing CB1 in the neocortex, hippocampus and basal ganglia (De Petrocellis et al, 2004). The pharmacological tool [3-(3carbamoylphenyl)phenyl]N-cyclohexylcarbamate (URB597) exhibits unique therapeutic potential as it is capable of inhibiting FAAH activity, thereby leading to accumulation of endocannabinoids, such as AEA and oleamide (Aguilera-Portillo et al, 2019;Maya-López et al, 2019). 2-Arachidonoylglycerol (2-AG), another major endocannabinoid which is mainly degraded by monoacylglycerol lipase (MAGL), has been shown to activate CB1 and CB2 receptors, in turn, exerting neuroprotective effects (Dinh et al, 2002;Mounsey et al, 2015).…”